image

RECENTLY ADDED

  • Drug Testing: Principles and Biological Matrices in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    This webinar will help build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The consensus document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    Michael M. Miller

    MD, LFAPA, DFASAM

    Michael M. Miller, MD, DFASAM, LFAPA, is the medical director of the Herrington Recovery Center at Rogers Memorial Hospital in Oconomowoc, Wisconsin. He is a board-certified general psychiatrist and addiction psychiatrist. Dr. Miller has practiced addiction medicine for more than 30 years and is certified in addiction medicine by the American Board of Addiction Medicine. He is a Life Fellow of the American Psychiatric Association (APA) and a Distinguished Fellow of the American Society of Addiction Medicine (ASAM). Dr. Miller is also an at-large director of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation, as well as a past president of ASAM. Dr. Miller has served on many task forces and councils of ASAM and the Wisconsin Medical Society (WMS), was chair of the WMS Commission on Addictive Diseases, and is current Speaker of the WMS House of Delegates and a member of the Society's Board of Directors. He serves as a faculty member for the Addiction Psychiatry Fellowship and the Addiction Medicine Fellowship at the University of Wisconsin School of Medicine and Public Health, where he is a Clinical Adjunct Professor. He also is an assistant clinical professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin. Dr. Miller was named the national physician Clinician of the Year by Addiction Professional magazine in 2011. He was the recipient of The ASAM Award in 2013.. Through 2015, he chaired the Steering Committee of ASAM's Practice Improvement and Performance Measurement Action Group. In June 2014, Dr. Miller was elected by the AMA House of Delegates to a four year term on the AMA Council on Science and Public Health.

    Learning Objectives: 
    -Describe the principles of drug testing in the assessment and monitoring of patients with, or at risk for, addiction 
    -Discuss the benefits and liabilities of the different biological matrices relative to their roles in drug testing 
    -Highlight the consensus document's recommendations and discuss their use in clinical practice

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Speaker Disclosure

    Name: Michael M. Miller, MD, DFASAM

    Nature of Relevant Financial Relationship

    Category

    Organization

    Type of Relationship

    Consultant

    World Meds

    Modest ($10,000 or less)

    Consultant

    BDSI

    Modest ($10,000 or less)

    Consultant

    Braeburn

    Modest ($10,000 or less)

    Consultant

    Purdue Pharma

    Modest ($10,000 or less)

    Consultant

    WPS

    Modest ($10,000 or less)

    Speaker/Speaker’s Bureau

    BDSI

    Modest ($10,000 or less)


    ASAM CME Committee and Reviewers Disclosure Listing

    NameCommercial InterestWhat was received?For what role?
    Catherine Friedman, MD, FAPA, FASAM, ChairNone  
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
    None   
    Noel Ilogu, MD, MRCP, DFASAMNone  
    Hebert L. Malinoff, MD, FACP, DFASAMNone  
    Edwin A. Salsitz, MD, DFASAMNone  
    John C. Tanner, DO, DABAM, DFASAM, CCFC, MROIndivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

  • Drug Testing: Special Populations and Additional Considerations in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today.

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    JoAn Laes

    MD

    JoAn Laes, MD, Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN; Consulting Medical Toxicologist, Minnesota Poison Control System, Minneapolis, MN; Medical Director, Mission Detox Center, Plymouth, MN

    Dr. Laes' practice is focused on inpatient addiction medicine and toxicology consultation and outpatient treatment of opioid and other substance use disorders.. She is board certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives

    • Identify the unique considerations in drug testing for special populations including adolescents and pregnant women. 
    • Summarize the consensus document's recommendations for drug testing for special populations and discuss how they should be used in practice.
    • Analyze the importance of practitioner documentation, confidentiality, language and attitude in addiction treatment.
    • Determine how to appropriately conduct drug testing on-site and/or choose a qualified laboratory.
  • Drug Testing: Process and Settings in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    image


    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. It will allow physicians to determine clearly how to choose and schedule a test, and respond to test results. It will also allow physicians to recognize the specific guidance warranted by different settings and levels of care including early intervention, outpatient services, intensive outpatient/partial hospitalization services, residential/inpatient care, medically management intensive inpatient services, and opioid treatment services. This webinar is intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population. 

    Ken Freedman

    MD, MS, MBA, DFASAM

    Since 2009, Dr. Freedman has worked as the Chief Medical Officer of Lemuel Shattuck Hospital in Boston; a facility that cares for many patients with substance use disorder, previously serving as Chief of Medicine. In addition, he is also a Clinical Professor of Medicine at Tufts University School of Medicine and Adjunct Clinical Associate Professor of Psychiatry at the University of Massachusetts Medical School. Dr. Freedman is board-certified in addiction medicine, internal medicine, and gastroenterology, and a member of the AMA, ACP, and AGA. He has been a member of ASAM since 1997.

    Over the past 20 years, Dr. Freedman has used his wide range of clinical and managerial skills to serve the needs of behavioral health and substance use patients. He teaches clinicians on the medically appropriate and humane treatment of pain disorders. Dr. Freedman’s professional commitment is to help move health care delivery towards the integration of medical care and substance use treatment in respectful and innovative ways. 

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives 
    1. Identify the fundamental components of the process of drug testing in addiction treatment. 
    2. Determine how to appropriately select the type of test for each patient, and how to respond to various test results. 
    3. Analyze the importance of and guidance around test scheduling and frequency. 
    4. Recognize the specific guidance warranted by drug testing in different settings and levels of care. 

  • The ASAM Review Course Spotlight Webinar Series (6 CME)

    Contains 24 Component(s), Medical Credits Offered

    This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine 2017.

    REVIEW COURSE ATTENDEES RECEIVE 25% OFF - 
    Use the promo code located in your syllabus when checking out to take advantage of this special deal!

    Looking to stay engaged and expand your ASAM Review Course experience? This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine. 

    Each webinar will be an hour long, with 30-45 minutes of lecture on the topic of the week and the rest saved for audience questions. Questions will be collected in advance from participants of the 2017 Review Course and as part of the webinar registration process – don’t miss your chance to ask the experts! 

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician at Mount Sinai Beth Israel, Department of Psychiatry and Behavioral Sciences, since 1983, and is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.  He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.  Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease.  He  lectures frequently and has been published on a variety of addiction medicine topics.

    Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT and PCSS-O mentoring programs. He has co-chaired  the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art Course and  is a reviewer for the Journal of Addiction Medicine. Currently Dr. Salsitz is the chair of the ASAM REMS ER/LA Opioids committee. Dr. Salsitz is a member of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He is the recipient of the 2014 ASAM Annual AwardDr. Salsitz is a member of the Medical Advisory Panel, for the New York State Office of Alcohol and Substance Abuse Services.

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.   A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego.  Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions.  She previously worked at a large outpatient addiction treatment program serving over 5000 patients.  Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders.  She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction.  During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships.  She completed a fellowship in Addiction Psychiatry at Yale.  During residency and her early faculty years, she founded and led the Yale Global Mental Health Program.  She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry.  She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program. 

    Abigail J. Herron

    DO, DFASAM

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

    Sharon Stancliff

    MD, FAAFP

    Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations. Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.

    Timothy Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency treatment program in Rochester, NY and as detoxification specialist for Syracuse Behavioral Health in Rochester, NY. Tim serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

  • The ASAM Review Course in Addiction Medicine 2017

    Contains 25 Product(s)

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 800 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives:

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2017 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/26/2017, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients